When Devices Aren’t One-Size-Fits-All: Why Sex-Specific Evidence Matters for Women’s Procedural Care

Why device evidence needs a women’s lens

Medical devices—from transcatheter valves to coronary stents—are often evaluated using populations that do not reflect the sex distribution of real-world recipients. That mismatch matters because anatomy, physiology and comorbidity patterns can change device performance, peri-procedural risk and longer-term outcomes. Recent regulatory signals and new women‑focused studies make this problem clearer and point to practical steps patients and clinicians can take now.

What the evidence shows

A systematic review of randomized trials for high‑risk implants found persistent underrepresentation of women, with many cardiovascular device trials enrolling substantially fewer women than expected from real‑world use ^[3]. An editorial summary of the review highlighted that, across nearly 200 device trials, women made up roughly one‑third of participants overall and only about 29% in many cardiovascular trials ^[4]. These gaps limit a trial’s ability to detect sex‑specific safety or effectiveness differences and complicate risk–benefit discussions for women.

Where sex‑focused data exist, they frequently show meaningful differences. The RHEIA trial — a randomized trial restricted to women with severe aortic stenosis — directly compared transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement and reported superior one‑year composite outcomes for TAVR in women, driven by lower rehospitalization and improved short‑term quality of life ^[5]. Large registry and meta‑analytic work add nuance: an international TAVR registry analysis found sex‑specific patterns in valve selection, procedural metrics and that severe prosthesis–patient mismatch (PPM) predicted mortality in men but not women after adjustment ^[6]. A large meta‑analysis reported that women had higher in‑hospital complications (bleeding, vascular events, stroke) but lower one‑year mortality versus men; analyses were heterogeneous and confounded by age, comorbidity and valve type ^[7].

Outside TAVR, the percutaneous coronary intervention (PCI) literature also shows sex differences in enrollment and event patterns: women are often underrepresented in PCI trials and may face different early complication profiles and absolute benefit–risk balances after revascularization ^[8].

Regulatory context and its limits

The FDA and its Center for Devices and Radiological Health (CDRH) have started to make sex‑specific evidence collection an explicit priority. CDRH’s Health of Women program sets strategic goals to improve sex‑ and gender‑specific analysis and to close device evidence gaps for women, emphasizing use of existing data sources where possible ^[2]. In December 2025 the FDA released a draft guidance recommending increased female enrollment across trials, prespecified sex analyses, and inclusion of sex‑specific information in regulatory submissions for drugs, biologics and devices — a signal that regulators expect sex to be treated as a core subgroup variable going forward ^[1].

Important caveats: the FDA document is a draft and non‑binding while public comment and implementation continue. Registries and meta‑analyses are observational and subject to confounding, and single women‑only RCTs like RHEIA provide strong internal evidence for that population but require replication and consideration of device iterations, operator experience and patient selection before broad generalization.

Practical implications for patients and clinicians

• Ask about sex‑specific evidence: Patients considering a device-based procedure can ask whether trial or registry data report sex‑stratified outcomes and how their own characteristics match study populations.
• Balance short‑ and long‑term outcomes: Some studies indicate women may have higher peri‑procedural complication rates yet better medium‑term survival after certain procedures. Discuss which outcomes matter most for the individual patient and how risks can be mitigated.
• Consider anatomy and device choice: Sex differences in body size, valve anatomy or vessel caliber can influence device selection and technical strategy. Clinicians should integrate sex‑aware procedural planning (valve sizing, access strategy, vascular closure) when evidence supports it.
• Trial participation matters: Greater female enrollment in device trials improves the precision of sex‑specific estimates. Clinicians and trial teams can support enrollment by addressing logistical and eligibility barriers that disproportionately affect women.

Where uncertainty remains

Despite emerging signals, uncertainty persists about which sex differences are biologically driven, which reflect selection or treatment patterns, and how device design evolution will change risks over time. Heterogeneity across studies—differences in device generation, operator skill, baseline risk and follow‑up—limits simple conclusions. For these reasons, routine prespecification of sex analyses in trials and more consistent sex‑stratified reporting in approvals and registries are needed to move from plausible differences to actionable guidance.

Bottom line

Device care is not inherently one‑size‑fits‑all. Recent women‑focused trials, registry findings and regulatory initiatives highlight both the problem (underrepresentation and inconsistent reporting) and pathways forward (sex‑prespecified analyses, device choice informed by sex‑specific data). For now, clinicians and patients should seek sex‑stratified evidence during shared decision making, and researchers and regulators should continue to prioritize designs and reporting that let sex‑specific signals be seen and acted upon.

"Where sex‑specific evidence exists, it changes decisions. Where it doesn't, we need better data — and clearer reporting — so women and clinicians can make informed choices."